Background A major challenge in stage II colorectal carcinoma is to identify patients with
increased risk of recurrence. Biomarkers that distinguish patients with poor prognosis from …

Purpose: Non-invasive monitoring of circulating tumor DNA (ctDNA) has the potential to be a
readily available measure for early prediction of clinical response. Here, we report on early …

Abstract Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect
minimal residual disease has been an area of increasing interest. Multiple methods have …

Neoadjuvant therapy is commonly used in patients with locally advanced or inoperable
breast cancer (BC). Neoadjuvant chemotherapy (NACT) represents an established …

Importance Liquid biopsy is an emerging tool with the potential to change oncologic care
practices. Optimal clinical applications for its use are currently undefined for surgical …

Background The current risk stratification system defined by clinicopathological features
does not identify the risk of recurrence in early-stage (stage I-II) colorectal cancer (CRC) with …

Importance There has been great enthusiasm for the emerging technology of molecular-
based tests to detect and quantify tumor DNA circulating in the bloodstream, colloquially …

The introduction of immunotherapy has ushered in a new era of anticancer therapy for many
cancer types including melanoma. Given the increasing development of novel compounds …

Liquid biopsy, in particular circulating tumor DNA (ctDNA) analysis, has paved the way for a
new noninvasive approach to cancer diagnosis, treatment selection and follow-up. As a …

Background: Loco-regional treatment strategies of colorectal cancer (CRC) metastases are
evolving, but biological markers that can benefit patients and assist physicians in clinical …